Samuelturner · Newsroom
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts
Long-term and real-world evidence reinforce BRUKINSA as the foundation of CLL treatment
Three oral presentations at ASCO highlight rapid acceleration of BeOne’s solid tumor pipeline
August 21, 2026
FDA Approves Tablet Form of Zanubrutinib for All Approved Indications
New formulation provides patients with a simplified dosing experience—reducing pill burden and enhancing ease of administration—while preserving flexible dosing options
August 19, 2026